ArticleFrontiers in pharmacology2025

Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058).

Fei Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.